|
See related Lantus information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
DKSH |
|
Contents |
Insulin glargine |
|
Indications |
DM in adults, adolescents & childn ≥6 yr.
Click to view Lantus detailed prescribing infomation |
|
Dosage |
Individualised dosage. By SC inj once daily at the same time everyday.
Click to view Lantus detailed prescribing infomation |
|
Overdosage |
View Lantus overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
[Click for Lantus detailed prescribing infomation] |
|
Special Precautions |
Impaired liver function & moderate to severe renal impairment. Hypo- & hyperglycaemia.
Click to view Lantus detailed prescribing infomation |
|
Adverse Drug Reactions |
Lipoatrophy or lipohypertrophy at the inj site. Rarely edema & allergic reactions including severe swelling of skin or mucous membranes, shortness of breath, fall in BP, shock.
View ADR Monitoring Form |
|
Drug Interactions |
Effects intensified by oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamides, & decreased by corticosteroids, OC, diuretics, INH, phenothiazine derivatives, sympathomimetic agents & thyroid hormones. β-blockers, clonidine & alcohol may weaken or potentiate its effects.
View more drug interactions with Lantus |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Lantus storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Lantus description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Lantus mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
